What is the predictive value of RECIST criteria following stereotactic lung radiation?

Stephanie Gulstene(London Health Sciences Centre), David A. Palma(Western University), Pencilla Lang(London Health Sciences Centre), Brian Yaremko(London Health Sciences Centre), Richard Inculet(London Health Sciences Centre), Edward Yu(University School), Richard Malthaner(London Health Sciences Centre), Mehdi Qiabi(London Health Sciences Centre), Joanna Laba(London Health Sciences Centre), Dalilah Fortin(London Health Sciences Centre), Andrew Warner(London Health Sciences Centre), Rahul Nayak(London Health Sciences Centre), Xiaotao Qu(The Affiliated Yongchuan Hospital of Chongqing Medical University), George Rodrigues(London Health Sciences Centre)
Radiotherapy and Oncology
November 1, 2023
10.1016/j.radonc.2023.109976
Cited by 19

Related Papers

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.3k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
|The Lancet Oncology|2016|1.1k